US FDA News: FDA approves first epoetin alfa biosimilar for the treatment of anemia

FDA approves Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia
Read more: FDA approves first epoetin alfa biosimilar for the treatment of anemia